Select Page
Albumin: The Next Generation Protein Therapeutic

Cosponsored by Novozymes Biopharma Inc.

About the Workshop

Saturday, July 12, 08:45 – 17:00

Organizers: Kenneth Howard, Aarhus University, Denmark, and Daniel Shelly, Novozymes Biopharma US, Inc., U.S.A.

Albumin is the most abundant human plasma protein that exhibits prolonged circulatory half-life and a predominant role in extracellular and intracellular transport of nutrients. Exploitation of these properties can be utilized for delivery of drug cargos and a paradigm shift in control of drug extended half-life and targeted delivery. This workshop assembles global leaders from both academia and industry in a unique forum to present and discuss the application of albumin in drug delivery. Biological mechanisms relevant for albumin drug delivery capabilities such as molecule binding, cellular receptor engagement and recycling, and its tuning through recombinant technology for modulation of pharmacokinetics are addressed. Clinical development and commercial albumin-based drug products such as albumin-binding prodrugs, genetic fusions, and nanoparticles are then described that highlight its emergence as the next-generation protein therapeutic.

Workshop Schedule

Speakers subject to change

 

08:45 – 09:00 Welcome and Introductions Kennth Howard, Aarhus University, Denmark
09:00 – 09:40 The Neonatal Fc Receptor (FcRn): A Controller of Albumin Homeostasis Jan Terje Andersen, Oslo University, Norway
09:40 – 10:20 Pharmacokinetics of Human Serum Albumin Variants Masaki Otagiri, Sojo University, Japan
10:20 – 10:50 Break
10:50 – 11:30 Clinical Impact of Albumin on Drug Delivery in Oncology-Albumin-Binding Prodrugs Felix Kratz, macromolecular Prodrugs, Tumor Biology Ctr, Germany
11:30 – 12:10 Engineered Albumins for the Enhancement of Drug Delivery Jason Cameron, Novozymes Biopharma UK, Ltd., United Kingdom
12:10 – 13:15 Lunch Break
13:15-13:55 Albumin-Based Extended Half-Life Studies Stefan Schulte, CSL Behring, U.S.A.
13:55 – 14:35 Prolonged Action of Albumin Binding Insulin: The Insulin Binding Analogue for Diabetes Treatment Ib Jonassen, Novo Nordisk A/S, Denmark
14:35 – 15:00 Break
15:00 – 15:40 Albumin Nanoparticle-Based Drug Delivery Neil Desai, Celgene, U.S.A.
15:40 – 16:20 Tregitope-Albumin Fusion Leslie Cousens,EpiVax, U.S.A.
16:20 – 17:00 Roundtable Discussion and Closing Remarks

Conference Website Here 

Mrs. Leslie Cousens

Mrs. Leslie Cousens

EpiVax Novo